Australia — Therapeutic Goods Administration
Tracked across 9 events · 83 articles · First seen May 05, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: The Australia — Therapeutic Goods Administration granted approval for 4DMedical Limited's CT:VQ technology, allowing its commercial deployment in Australia. This regulatory body's decision is crucial for market access.
Jun 29, 2026 · 8 articles
Business
Impact: The Australia — Therapeutic Goods Administration (TGA) approved orelabrutinib in Australia, making it available as a new treatment option for Mantle Cell Lymphoma.
May 27, 2026 · 6 articles
Regulatory
Impact: TGA conducted a Pre-Approval Inspection, enabling Cambrex's High Point facility to manufacture APIs for the Australian market.
Jul 20, 2026 · 8 articles
Business
Impact: The TGA's approval facilitated the commercial use of Idefirix in Australia, marking a regulatory success for the product in the region.
Aug 18, 2026 · 6 articles
Regulatory
Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a…
Impact: Australian regulator that required drugmakers to include warnings about a potentially increased NAION risk with certain GLP-1 medicines, adding to the global regulatory pressure on the drugmakers.
Sep 21, 2026 · 20 articles
Tech
Impact: The Australia — Therapeutic Goods Administration (TGA) is the regulatory body in Australia whose filing was completed for the clinical trial. Its approval is essential for the trial's conduct.
Jun 03, 2026 · 11 articles
Business
Impact: The Australia — Therapeutic Goods Administration in Australia oversees the Authorized Prescriber Scheme, under which Optimi Health's psilocybin is prescribed and reimbursed, facilitating patient access to psychedelic medicine.
Jun 29, 2026 · 12 articles
Tech
Impact: The Australian Australia — Therapeutic Goods Administration previously approved REDEMPLO (plozasiran), expanding its global reach.
May 26, 2026 · 6 articles
55
Australia — Therapeutic Goods Administration required warningsGLP-1 Vision Loss Lawsuits...
ERGEN INTELLIGENCE
Track Australia — Therapeutic Goods Administration live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard